ARTICLE | Company News
Origen Therapeutics Inc. other research news
September 10, 2001 7:00 AM UTC
Origen received two $100,000 Phase I SBIR grants from the National Institute of General Medical Sciences. The first grant will be used to develop a tissue-specific gene expression vector enabling the ...